title: External validation of the UCSF-CAPRA (University of California, San Francisco, Cancer of the Prostate Risk Assessment) in Japanese patients receiving radical prostatectomy.
abstract: OBJECTIVE
  In 2005, the University of California, San Francisco developed the Cancer of the Prostate Risk Assessment (UCSF-CAPRA) score as a new risk stratification tool. The UCSF-CAPRA, which ranges from 0 to 10 points, consists of five clinical variables, prostate-specific antigen, Gleason score, T stage, percent of positive biopsies and age. The aim of this study was to validate the UCSF-CAPRA score for Japanese prostate cancer patients receiving radical prostatectomy using the contemporary Gleason grading.
  
  
  METHODS
  From 1999 to 2010, 211 men who underwent radical prostatectomy were used for validation. Biochemical progression-free survival was calculated using the Kaplan-Meier method and the UCSF-CAPRA and D'Amico risk categories were compared using the log-rank method. The concordance index (c-index) for the UCSF-CAPRA and D'Amico risk classification was calculated.
  
  
  RESULTS
  Using the UCSF-CAPRA score, 85 (40.3%), 106 (50.2%) and 20 (9.5%) subjects were stratified as 0-2 points (low risk), 3-5 points (intermediate risk) and 6-10 points (high risk). Using the D'Amico risk criteria, 66 (31.3%), 89 (42.2%) and 56 (26.5%) were stratified as low-, intermediate- and high-risk groups, respectively. The Kaplan-Meier analysis showed that the UCSF-CAPRA divided the patients significantly into each risk category. There was no significant difference between low and intermediate in the D'Amico risk classification. The c-index of the UCSF-CAPRA and D'Amico classification was 0.755 and 0.713, respectively.
  
  
  CONCLUSIONS
  The UCSF-CAPRA is an acceptable risk category tool comparable to that of the D'Amico risk classification for Japanese prostate cancer patients receiving radical prostatectomy in the contemporary Gleason grading era.
authors.affiliation: Division of Urology, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Asahimachi 1, Chuo-ku, Niigata 951-8510, Japan.
authors.forename: Fumio
authors.initials: F
authors.lastname: Ishizaki
authors.forename: Md Aminul
authors.initials: MA
authors.lastname: Hoque
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Nishiyama
authors.forename: Takashi
authors.initials: T
authors.lastname: Kawasaki
authors.forename: Takashi
authors.initials: T
authors.lastname: Kasahara
authors.forename: Noboru
authors.initials: N
authors.lastname: Hara
authors.forename: Itsuhiro
authors.initials: I
authors.lastname: Takizawa
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Saito
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Kitamura
authors.forename: Kohei
authors.initials: K
authors.lastname: Akazawa
authors.forename: Kota
authors.initials: K
authors.lastname: Takahashi
mesh_terms: D044466:Asian People; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000175:diagnosis* / Q000601:surgery; D009367:Neoplasm Staging; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology* / Q000601:surgery*; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D012495:San Francisco; D015996:Survival Rate
chemical_list: D017430:Prostate-Specific Antigen